002581 *ST未名医药
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-5.279-6.176-6.879-14.929-0.614
总资产报酬率 ROA (%)-4.531-5.329-6.058-12.770-0.521
投入资产回报率 ROIC (%)-5.054-5.887-6.645-14.132-0.566

边际利润分析
销售毛利率 (%)12.92952.84279.78580.59678.657
营业利润率 (%)-109.946-65.134-30.930-68.2559.430
息税前利润/营业总收入 (%)-112.604-64.965-41.749-71.1785.609
净利润/营业总收入 (%)-111.730-58.525-39.632-74.952-0.240

收益指标分析
经营活动净收益/利润总额(%)86.80283.27852.37557.758-1,464.805
价值变动净收益/利润总额(%)5.212-9.585-42.915-55.1261,708.919
营业外收支净额/利润总额(%)2.534-1.97223.7416.352-164.616

偿债能力分析
流动比率 (X)4.6433.2999.0433.7181.423
速动比率 (X)3.6502.8108.0793.0791.203
资产负债率 (%)8.60810.2387.9066.99213.571
带息债务/全部投入资本 (%)2.8793.2640.3910.5667.092
股东权益/带息债务 (%)3,331.7742,927.52624,345.70017,332.7481,296.269
股东权益/负债合计 (%)1,007.824829.8421,108.0081,265.802612.512
利息保障倍数 (X)-561.84359.57635.077-41.7192.742

营运能力分析
应收账款周转天数 (天)448.523222.388103.234125.947211.052
存货周转天数 (天)250.373240.136407.533356.911340.998